Compare Neurocrine Biosciences Inc (NBIX) vs Direxion Daily Semiconductor Bear 3X Shares (SOXS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Direxion Daily Semiconductor Bear 3X Shares — how do they compare? Neurocrine Biosciences Inc trades at $143.97 (market cap $14.36B), while Direxion Daily Semiconductor Bear 3X Shares trades at $34.38 (market cap $1.96B). The key difference: Neurocrine Biosciences Inc is far larger — about 7.3× Direxion Daily Semiconductor Bear 3X Shares's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Direxion Daily Semiconductor Bear 3X Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Direxion Daily Semiconductor Bear 3X Shares for 11 Days on average.
| NBIX | SOXS | |
|---|---|---|
Market Cap | $14.36B | $1.96B |
Volume | 1,237,180 | 113,512,541 |
Sector | Health | Leveraged / Inverse |
52-Week High | $185.50 | $988.00 |
52-Week Low | $123.10 | $29.62 |
Typical Hold Time | 23 Days | 11 Days |
Enterprise Value | $14.37B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $142.44, down 0.72% with bearish technical signals but strong fundamentals including three consecutive quarterly EPS beats. The company shows robust profitability with 20.91% net margin and 22.09% ROE, supported by growing revenue from $2.9B to $3.4B projected. Recent news highlights pipeline development and conference participation.
Wall Street maintains strong bullish sentiment with 86% buy ratings and $204.18 consensus target, representing 43% upside. Key risks include INGREZZA pricing pressure in 2029 and execution challenges as the company diversifies beyond its main product. The stock offers growth potential but faces near-term technical headwinds.
SOXS, the Direxion Daily Semiconductor Bear 3X ETF, is trading at $34.39, up 12.22% today, reflecting its inverse leveraged exposure to semiconductor stocks. The technical picture is bearish overall, with moving averages signaling a downtrend. Recent news highlights the fund's volatility and tactical use during semiconductor sector pullbacks, driven by factors like AI demand fluctuations and competitive pressures on chipmakers.
The outlook for SOXS remains highly speculative, suitable only for short-term traders betting against semiconductors. Key risks include the fund's decay from daily rebalancing, reliance on semiconductor volatility, and potential for rapid losses if the sector rallies. Investors should avoid long-term holdings due to structural erosion and elevated volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Direxion Daily Semiconductor Bear 3X Shares
SOXS is a leveraged ETF that seeks daily investment results corresponding to 300% of the inverse (opposite) of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bearish (short) position on the semiconductor sector. Due to the effects of compounding and leverage, SOXS is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXS →
